{"id":831325,"date":"2025-03-30T11:03:12","date_gmt":"2025-03-30T15:03:12","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/medtronic-evolut-tavr-system-shows-durable-clinical-outcomes-and-outstanding-valve-performance-at-five-years-in-low-risk-aortic-stenosis-patients\/"},"modified":"2025-03-30T11:03:12","modified_gmt":"2025-03-30T15:03:12","slug":"medtronic-evolut-tavr-system-shows-durable-clinical-outcomes-and-outstanding-valve-performance-at-five-years-in-low-risk-aortic-stenosis-patients","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/medtronic-evolut-tavr-system-shows-durable-clinical-outcomes-and-outstanding-valve-performance-at-five-years-in-low-risk-aortic-stenosis-patients\/","title":{"rendered":"Medtronic Evolut\u2122 TAVR system shows durable clinical outcomes and outstanding valve performance at five years in low-risk aortic stenosis patients"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n
\n GALWAY<\/span>, Ireland<\/span> and CHICAGO<\/span><\/span>, March 30, 2025<\/span><\/span> \/PRNewswire\/ — Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced late-breaking data on five-year outcomes from the Evolut Low Risk Trial. Data shows, versus surgery, the Evolut\u2122 transcatheter aortic valve replacement (TAVR) system delivers a numerically lower rate of all-cause mortality or disabling stroke at five years, strong valve performance and durable clinical outcomes. The findings were presented as late-breaking clinical science at the American College of Cardiology’s Annual Scientific Session & Expo and simultaneously published in the JACC, the flagship journal of the American College of Cardiology<\/a>.<\/p>\n

The Evolut Low Risk Trial was a randomized, multicenter, international study assessing the safety and efficacy of the Evolut TAVR system versus surgery in low-risk patients. These patients had a predicted 30-day mortality risk <3%, as assessed by a local heart team. 1,414 patients were randomized, with 730 receiving TAVR with either a Medtronic Evolut R, PRO, or CoreValve\u2122 and 684 undergoing surgery.<\/p>\n

“Results at five years support Evolut’s supra-annular, self-expanding TAVR as a safe, effective, and durable alternative to surgery for patients with severe aortic stenosis, regardless of their surgical risk,” said Michael J. Reardon<\/span>, M.D., Allison Family Distinguished Chair of Cardiovascular Research and professor of cardiothoracic surgery at the Houston Methodist Hospital and principal investigator of the trial. “The lower mortality risk and strong valve performance is meaningful for clinicians in evaluating treatment approaches that prioritize the overall well-being of patients.”<\/p>\n

Patients with severe aortic stenosis who were treated with either Evolut TAVR or surgery showed comparable rates of all-cause mortality or disabling stroke at 5 years (Evolut TAVR [15.5%] and surgery [16.4%]; p=0.47). Additional findings at five years include:<\/p>\n